PRKAA1 and cardiac hypertrophy: Our findings are consistent with studies showing that AMPK activation or AdipoRon treatment mitigates L-Thyroxine- or isoproterenol-induced cardiac hypertrophy by enhancing myocardial mitochondrial energy metabolism pathways [49,50].